Skip to content

Journey Medical Corporation DERM Free cash flow margin

Free cash flow margin at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
9.8%-2.8pp
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
3.3%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-52.5%-21.9pp
HRO
HarrowHROW
5.7%+5.0pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
34.9%-15.2pp
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-30.3%

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

Based on trailing twelve months.

The official record: Journey Medical Corporation’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's free cash flow margin?
Journey Medical Corporation (DERM) reported free cash flow margin of -43% in Q4 2024.
What is the long-term trend for Journey Medical Corporation's free cash flow margin?
Over 2 years (2021 to 2024), Journey Medical Corporation's free cash flow margin has grown at a 252.7% compound annual growth rate (CAGR), from -3.5% to -43%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.